Galena Biopharma fka GALE

[JonathanTel]

So, after researching for a short bit into the CT Order recently posted. this is what I have seen so far from the 2013 Full Year 10K as well as the 2014 Q1 Earnings Report pertaining to the "Exhibit #'s" that were listed in the recent SEC/CTO form, as noted below:

Exhibit 2.1 through March 17, 2019:

Unit Purchase Agreement, dated as of January 12, 2014, between Galena Biopharma, Inc. and Mills Pharmaceuticals, LLC.+**

* this "Exhibit" was noted on both the Full Year 2013 and Q1 2014 Earning Reports

Exhibit 10.36 through January 13, 2024:

License and Development Agreement, dated January 13, 2014, between Galena Biopharma, Inc. and Dr. Reddy’s Laboratories, Ltd.+**

Exhibit 10.37 through December 20, 2016:

Exclusive License Agreement, dated as of December 20, 2013, between Mills Pharmaceuticals, LLC and BioVascular, Inc.+**


Any thoughts on if this is anything for the "positive" for us, or is it just "standard practice"?